PharmaZell prices €305 million of term debt at Euribor plus 400 bps

By Sara Rosenberg

New York, April 14 – PharmaZell wrapped syndication of a €15 million add-on term loan B and a repricing of its existing €290 million term loan B at pricing of Euribor plus 400 basis points with a 0% floor and a par issue price, according to a market source.

HSBC is the agent on the deal.

The add-on term loan will be used to repay revolving credit facility borrowings and add cash to the balance sheet, and the repricing will take the existing term loan B down from Euribor plus 450 bps with a 0% floor.

Bridgepoint is the sponsor.

PharmaZell is a Germany-based manufacturer of niche active pharmaceutical ingredients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.